Online inquiry

IVTScrip™ mRNA-Anti-FGF23, KRN-23(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9999MR)

This product GTTS-WQ9999MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets FGF23 gene. The antibody can be applied in Dermatological genetic disorders research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_020638.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8074
UniProt ID Q9GZV9
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FGF23, KRN-23(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9999MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6142MR IVTScrip™ mRNA-Anti-CTLA4, CP-675(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CP-675
GTTS-WQ13193MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA PF-04950615
GTTS-WQ8999MR IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMA-638
GTTS-WQ779MR IVTScrip™ mRNA-Anti-AXL, Ab-2(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA Ab-2
GTTS-WQ1321MR IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABT-700
GTTS-WQ13117MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA PF-04360365
GTTS-WQ11870MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MLN-0264
GTTS-WQ9498MR IVTScrip™ mRNA-Anti-EGFR, J2898A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA J2898A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW